advertisement
Li W 18
Showing records 1 to 18 | Display all abstracts from Li W105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Xiong K
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Sun X; Liu Q
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Wang L
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Tang X
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Li W
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yao K
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Wang W
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Li Y
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Meng J; Gong X
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yang J
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Lu P
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Zhang M
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Liang X
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yuan H
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Huang J
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Zheng Y
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Huang W
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Li W; Peng H
BMC Ophthalmology 2022; 22: 332
